



03-08-04

Docket 17641 (BOT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: MITCHEL F. BRIN, et al.

Serial No.: 10/754,364

Filed: January 8, 2004

For: METHODS FOR TREATING
VASCULAR DISORDERS

Examiner:

Group Art Unit:

Irvine, California

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Applicants provide with regard to the above-identified patent application entitled METHODS FOR TREATING VASCULAR DISORDERS, one copy of documents of which they are aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of the documents submitted is set forth on the attached Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, the disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

Date: March 4, 2004


Stephen Donovan
Attorney of Record
Registration Number 33,433

Please direct all inquiries and correspondence to:

Stephen Donovan
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534
Tel: (714) 246-4026
Fax: (714) 246-4249

CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. § 1.10

I hereby certify that this Information Disclosure Statement and the documents referred to as enclosed therein are being deposited with the United States Postal Service on this date March 4, 2004 in an envelope as "Express Mail Post Office to Addressee" Mailing Label number EV193717195US addressed to Mail Stop: Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Susan Bartholomew
Name of person mailing paper


Signature of person signing paper

Date March 4, 2004

PATENT AND TRADEMARK OFFICE
FORM PTO-1449

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17641 (BOT)		SERIAL NO.: 10/754,364
APPLICANT: MITHCEL F. BRIN		TITLE: METHODS FOR TREATING VASCULAR DISORDERS
FILING DATE: January 8, 2004		GROUP:

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	09/371,354		Donovan, Stephen			8/10/1999
	AB	10/114,740		Brooks, Greg			4/1/2002
	AC	10/194,805		Donovan, Stephen			7/11/2002
	AD	5,437,291	8/1/1995	Pasricha et al.			
	AE	5,670,484	9/23/1997	Binder, William			
	AF	5,714,468	2/3/1998	Binder, William			
	AG	5,766,605	6/16/1998	Sanders et al.			
	AH	5,989,545	11/23/1999	Foster et al.			
	AI	6,063,768	5/16/2000	First, Eric			
	AJ	6,139,845	10/31/2000	Donovan, Stephen			
	AK	6,265,379	7/24/2001	Donovan, Stephen			
	AL	6,299,893	10/9/2001	Schwartz et al.			
	AM	6,306,423	10/23/2001	Donovan et al.			
	AN	6,312,708	11/6/2001	Donovan, Stephen			
	AO	6,358,926	3/19/2002	Donovan, Stephen			
	AP	6,423,319	7/23/2002	Brooks et al.			
	AQ	6,458,365	10/1/2002	Aoki et al.			
	AR	6,464,986	10/15/2002	Aoki et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA	WO 01/10458	2/15/01	PCT			Yes
	BB	WO 03/084567	10/16/03	PCT			Yes

OTHER ART

(Including Author; Title, Date, Pertinent Pages, etc.)


	CA	Bigalke H., et al., <i>Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture</i> , Brain Research 360;318-324:1985
--	----	--

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PATENT AND TRADEMARK OFFICE
FORM PTO-1449

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17641 (BOT)		SERIAL NO.: 10/754,364
APPLICANT: MITHCEL F. BRIN		TITLE: METHODS FOR TREATING VASCULAR DISORDERS
FILING DATE: January 8, 2004		GROUP:

	CB	Bigalke H., et al., <i>Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations From Rat Brain and Spinal Cord</i> , Naunyn-Schmiedeberg's Arch Pharmacol 316;244-251:1981
	CC	Binz T. et al., <i>The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins</i> , J Biological Chemistry 265(16);9153-9158:1990
	CD	Bushara K., <i>Botulinum toxin and rhinorrhea</i> , Otolaryngol Head Neck Surg 1996;114(3):507
	CE	Duggan et al., <i>A Survey of Botulinum neurotoxin substrate expression in cells; Mov Disord</i> , 10(3):376:1995
	CF	Gonelle-Gispert et al., <i>Snap-25a and -25b isoforms are both expressed in insulin-secreting cells and can function in insulin secretion; Biochem J</i> 1;339 (pt 1):159-65:1999
	CG	Habermann E., et al., <i>Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release From Cultured Mouse Brain</i> , J Neurochem 51(2);522-527:1988
	CH	Habermann E., <i>Inhibition by Tetanus and Botulinum A Toxin of the release of [3H]Noradrenaline and [3H]GABA From Rat Brain Homogenate</i> , Experientia 44;224-226:1988
	CI	<i>Harrison's Principles of Internal Medicine</i> (1998), edited by Anthony Fauci et al., 14th edition, published by McGraw Hill
	CJ	Jankovic J. et al., <i>Therapy With Botulinum Toxin</i> , Marcel Dekker, Inc., (1994), page 5, 150
	CK	Moro E., et al, <i>Suppression of syncopes after botulinum toxin treatment</i> , Mov Disord 2002;17(Suppl 5):S242 ABS P780
	CL	Moyer E et al., <i>Botulinum Toxin Type B: Experimental and Clinical Experience</i> , being chapter 6, pages 71-85 of "Therapy With Botulinum Toxin", edited by Jankovic, J. et al. (1994), Marcel Dekker, Inc.
	CM	Naumann et al., <i>Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions</i> ; European J. Neurology 6 (Supp 4): S111-S1150:1999
	CN	Pearce, L.B., <i>Pharmacologic Characterization of Botulinum Toxin For Basic Science and Medicine</i> , Toxicon 35(9);1373-1412 at 1393
	CO	Ragona et al., <i>Management of Parotid Sialocele with Botulinum Toxin; The Laryngoscope</i> 109:1344-1346:1999


EXAMINER _____

DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PATENT AND TRADEMARK OFFICE
FORM PTO-1449

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17641 (BOT)		SERIAL NO.: 10/754,364
APPLICANT: MITHCEL F. BRIN		TITLE: METHODS FOR TREATING VASCULAR DISORDERS
FILING DATE: January 8, 2004		GROUP:

	CP	Sanchez-Prieto, J., et al., <i>Botulinum Toxin A Blocks Glutamate Exocytosis From Guinea Pig Cerebral Cortical Synaptosomes</i> , Eur J. Biochem 165;675-681:1897
	CQ	Sterodimas, A., et al., <i>Successful use of botulinum toxin-A for the treatment of neck and anterior chest wall flushing</i> , Clinical and Experimental Dermatology, 2003 Blackwell Publishing Ltd., Vol. 28, Pg. 592-594
	CR	Schantz, E.J., et al, <i>Properties and use of Botulinum toxin and Other Microbial Neurotoxins in Medicine</i> , Microbiol Rev. 56;80-99:1992
	CS	Singh, <i>Critical Aspects of Bacterial Protein Toxins</i> , pages 63-84 (chapter 4) of Natural Toxins II, edited by B.R. Singh et al., Plenum Press, New York (1976)
	CT	Sloop et al., <i>Reconstituted Botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use</i> ; Neurology, 48:249-53:1997.
	CU	Tugnoli V., et al., <i>The role of gustatory flushing in Frey's syndrome and its treatment with botulinum toxin type A</i> , Clin Auton Res 2002;12(3):174-178

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.